CAM
ACAD icon

Crown Advisors Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Crown Advisors Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-30,000
Closed -$554K – 42
2024
Q1 		$554K Hold
30,000
– – 0.34% 43
2023
Q4 		$939K Hold
30,000
– – 0.64% 40
2023
Q3 		$625K Hold
30,000
– – 0.44% 44
2023
Q2 		$718K Hold
30,000
– – 0.47% 49
2023
Q1 		$564K Buy
+30,000
New +$571K 0.42% 45
2022
Q4 		– Sell
-30,000
Closed -$490K – 43
2022
Q3 		$490K Buy
+30,000
New +$486K 0.49% 42

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Crown Advisors Management's ACAD Position: Q2 2024 in Review

Crown Advisors Management sold out of Acadia Pharmaceuticals (ACAD) in Q2 2024, closing a stake of 30,000 shares — an estimated $554K sold.

Crown Advisors Management first reported a position in ACAD in Q3 2022 and held it in 6 quarters. The position peaked at $939K in Q4 2023. 264 funds tracked by Wall St. Rank hold ACAD as of Q2 2024.

  • Crown Advisors Management reported no remaining Acadia Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Crown Advisors Management sold 30,000 Acadia Pharmaceuticals shares in Q2 2024, an estimated $554K.
  • Crown Advisors Management first reported a position in Acadia Pharmaceuticals in Q3 2022 and held it in 6 quarters.
  • Crown Advisors Management's Acadia Pharmaceuticals position peaked at $939K in Q4 2023.
  • 264 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2024.

Based on Crown Advisors Management's 13F filing for Q2 2024, filed 8 Aug 2024.